Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Three ‘clinically important’ cancer trials could not open due to funding issues

By Mindo - 03rd Apr 2018 | 25 views

CTI, the largest collaborative cancer research infrastructure in Ireland, has been unable to open these trials due to a 20 per cent reduction in its grant from the Health Research Board (HRB) for 2016-2018. Currently, CTI receives over €3 million annually from the HRB, most of which is distributed to cancer trials research units nationally.

The <em>National Cancer Strategy 2017-2026</em> commits to doubling the number of people with cancer on therapeutic clinical trials to 6 per cent by 2020.

CTI has submitted an application to the HRB for the 2019-2021 funding round.

In the context of the key role of its network of research units in achieving the Strategy’s target, it is “hopeful” the Department of Health and/or HRB may be able to consider reversing the funding cut.

Of the three trials that CTI could not open in 2017, one involves chemotherapy drugs, one involves surgery and the other is a translational study.

“Because CTI does not have funding within its current budget profile to open these three trials in Ireland, it means that qualifying Irish patients will not get access to these potentially promising treatments unless alternative funding become available,” said CTI’s spokesperson, who also confirmed that the trials had not opened by other means.

CTI’s key scientific objective is to build its portfolio of in-house academic trials with translational sub-studies and expand its participation in international collaborative studies.

“An in-house academic trial usually refers to trials which have been instigated by clinical investigators, sponsored by an academic group like CTI and are funded by public funds, like our HRB grant or the Irish Cancer Society grant. The trial may be significant in the development of new approaches to treatment.”

An example is the CTI-sponsored Neo-AEGIS Trial, which is comparing two standard of care treatments for oesophageal cancer.

A Department spokesperson said it will “examine the possibilities for increased funding in the context of competing demands across the health sector”.

At any one time, there could be approximately 6,000 patients on a cancer trial in Ireland.

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read